丸美生物(603983) - 2025 Q2 - 季度财报
MarubiMarubi(SH:603983)2025-08-22 12:00

Financial Performance - The company's operating revenue for the first half of 2025 reached ¥1,769,193,475.01, representing a year-on-year increase of 30.83% compared to ¥1,352,290,860.56 in the same period last year[21]. - The total profit for the first half of 2025 was ¥240,776,293.10, which is a 7.17% increase from ¥224,659,830.54 in the previous year[21]. - The net profit attributable to shareholders of the listed company was ¥185,740,286.43, reflecting a 5.21% increase from ¥176,537,086.78 in the same period last year[21]. - The basic earnings per share for the first half of 2025 was ¥0.46, up 4.55% from ¥0.44 in the same period last year[22]. - The weighted average return on net assets increased to 5.40%, up from 5.19% in the previous year, marking an increase of 0.21 percentage points[22]. Revenue Sources - The increase in operating revenue is primarily attributed to sustained growth in online channels[22]. - The Marubi brand generated 1.250 billion yuan in revenue, up 34.36% year-on-year, while the PL Lianhuo brand reached 516 million yuan, increasing by 23.87%[29]. - The online channel generated revenue of 1.571 billion yuan, accounting for 88.87% of total revenue, with a year-on-year growth of 37.85%[36]. - The offline channel achieved revenue of 197 million yuan, representing 11.13% of total revenue, with a year-on-year decline of 7.07%[36]. Expenses and Costs - Operating costs increased to ¥449,287,741.20, reflecting a growth of 31.21% due to higher sales revenue[47]. - Sales expenses rose to 1 billion yuan, a year-on-year increase of 39.31%, primarily due to rising online traffic costs and ongoing brand building efforts[29]. - Research and development expenses amounted to 40.70 million yuan, reflecting a year-on-year growth of 13.53%[29]. Cash Flow - The net cash flow from operating activities increased by 97.41%, amounting to ¥115,647,247.15 compared to ¥58,582,996.50 in the previous year[21]. - Operating cash inflow for the first half of 2025 reached ¥1,775,691,102.87, a 41.0% increase from ¥1,259,531,556.22 in the first half of 2024[110]. - Cash outflow from investing activities totaled ¥235,365,414.78, compared to ¥483,688,388.40 in the previous year, indicating a reduction of 51.3%[111]. Market Position and Strategy - The company received the "2025 Forbes China Beauty Industry Excellence Brand 100" award, further solidifying its market position[34]. - The company is investing in the "smart cosmetics manufacturing plant" and "marketing upgrade and operations headquarters" projects[50]. - The company faces increasing market competition due to the rapid growth of e-commerce and the entry of foreign brands into the domestic market[56]. Shareholder Information - The company plans to distribute a cash dividend of ¥2.50 per 10 shares (including tax) to shareholders registered on the dividend distribution date[6]. - The company reported a profit distribution of 208,520,000.00 to shareholders, indicating a commitment to returning value to investors[117]. - The total number of ordinary shareholders as of the end of the reporting period is 17,371[88]. Innovation and Development - The company launched the innovative "Super Mask" product, which quickly gained market recognition due to its unique formula and effectiveness[31]. - The company established three new collaborative projects in academic and industrial innovation, expanding its expert pool to 110 members, enhancing innovation capabilities and technical reserves[32]. - In the first half of 2025, the company applied for 25 new patents, bringing the total to 619, with 16 new authorized invention patents, totaling 365 authorized patents[32]. Financial Health and Assets - The company's net assets attributable to shareholders at the end of the reporting period were ¥3,365,535,062.95, a slight decrease of 0.44% from ¥3,380,406,892.85 at the end of the previous year[21]. - Total assets decreased by 5.87% to ¥4,765,479,158.62 from ¥5,062,564,094.81 at the end of the previous year[21]. - The total liabilities and equity structure remains robust, supporting future growth initiatives[96]. Compliance and Governance - The financial report was approved for release on August 21, 2025, indicating timely compliance with regulatory requirements[123]. - The company has confirmed its ability to continue as a going concern for at least 12 months from the reporting date, with no significant issues affecting its operational capacity[125]. - The company will ensure that the IPO prospectus does not contain any false records or significant omissions, and it will assume legal responsibility for its accuracy and completeness[68].